Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03216499 · ClinicalTrials.gov registry record · Phase 2
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03216499 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 24 participants.
The verdict
NCT03216499, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- OTHER Pharmacogenomic Study
- DRUG HIF-2alpha Inhibitor PT2385
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2020-06-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03216499
The ClinicalTrials.gov registry entry for NCT03216499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03216499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03216499 about?
NCT03216499 is a clinical study titled "HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma". This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03216499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-09-14. Estimated completion is 2020-06-05.
What interventions are being tested in trial NCT03216499?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Pharmacogenomic Study (OTHER), HIF-2alpha Inhibitor PT2385 (DRUG).
Who is sponsoring clinical trial NCT03216499?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.